Single-Center Experience With Inner-Branched Endograft for the Treatment of Pararenal Abdominal Aortic Aneurysms.

IF 1.5 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE
Journal of Endovascular Therapy Pub Date : 2025-08-01 Epub Date: 2023-10-16 DOI:10.1177/15266028231204286
Ozan Yazar, Michaël Huysmans, Mathieu Lacquet, Pieter B Salemans, Chun-Yu Wong, Lee H Bouwman
{"title":"Single-Center Experience With Inner-Branched Endograft for the Treatment of Pararenal Abdominal Aortic Aneurysms.","authors":"Ozan Yazar, Michaël Huysmans, Mathieu Lacquet, Pieter B Salemans, Chun-Yu Wong, Lee H Bouwman","doi":"10.1177/15266028231204286","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To report a single-center result of patients with pararenal aneurysms treated with inner-branched endograft.</p><p><strong>Materials and methods: </strong>This retrospective study analyzed prospectively collected data of patients treated with elective inner-branched endovascular aneurysm repair (iBEVAR) using an Artivion<sup>®</sup> E-xtra custom-made endograft. Primary endpoints were clinical and technical success after iBEVAR. Secondary endpoints were overall survival, target vessel patency during follow-up, aneurysm-related mortality, and freedom from reintervention.</p><p><strong>Results: </strong>Over a 56-month period, a total of 23 patients (19 men; 72.3±7.2 years) were treated with iBEVAR with a mean follow-up of 15 months. Technical success was achieved in 96% of procedures, incorporating 87 inner branches. Two (8.3%) intraoperative complications (target vessel dissection) were reported, without additional reinterventions needed. Two (8.3%) patients died within 30 days after initial procedure. One due to respiratory failure and the other from an ischemic stroke. During follow-up, 3 patients (13%) required reintervention, either to repair a type I or type III endoleak (n=2) or to place an iliac-branched device, that did not succeed during the initial iBEVAR procedure (n=1). Primary target vessel patency and freedom from reintervention during follow-up was, respectively, 98.9% and 87%. We revealed no aneurysm-related mortality. Overall survival was 78.3%.</p><p><strong>Conclusion: </strong>The present study confirms previous findings that iBEVAR on the Artivion<sup>®</sup> E-xtra design platform is an effective and safe procedure achieving high technical success rate in the treatment of pararenal abdominal aortic aneurysms.Clinical ImpactInner branched stent-graft configuration combines the benefits of FEVAR and outer-branched stent-graft technology. Implementation of inner branches in stent-grafts is gradually becoming more widespread for the treatment of aneurysms. This report supports the safe and high technical success rate of inner branched stent-grafts in treatment of pararenal abdominal aortic aneurysms.</p>","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":" ","pages":"1119-1126"},"PeriodicalIF":1.5000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Endovascular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15266028231204286","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To report a single-center result of patients with pararenal aneurysms treated with inner-branched endograft.

Materials and methods: This retrospective study analyzed prospectively collected data of patients treated with elective inner-branched endovascular aneurysm repair (iBEVAR) using an Artivion® E-xtra custom-made endograft. Primary endpoints were clinical and technical success after iBEVAR. Secondary endpoints were overall survival, target vessel patency during follow-up, aneurysm-related mortality, and freedom from reintervention.

Results: Over a 56-month period, a total of 23 patients (19 men; 72.3±7.2 years) were treated with iBEVAR with a mean follow-up of 15 months. Technical success was achieved in 96% of procedures, incorporating 87 inner branches. Two (8.3%) intraoperative complications (target vessel dissection) were reported, without additional reinterventions needed. Two (8.3%) patients died within 30 days after initial procedure. One due to respiratory failure and the other from an ischemic stroke. During follow-up, 3 patients (13%) required reintervention, either to repair a type I or type III endoleak (n=2) or to place an iliac-branched device, that did not succeed during the initial iBEVAR procedure (n=1). Primary target vessel patency and freedom from reintervention during follow-up was, respectively, 98.9% and 87%. We revealed no aneurysm-related mortality. Overall survival was 78.3%.

Conclusion: The present study confirms previous findings that iBEVAR on the Artivion® E-xtra design platform is an effective and safe procedure achieving high technical success rate in the treatment of pararenal abdominal aortic aneurysms.Clinical ImpactInner branched stent-graft configuration combines the benefits of FEVAR and outer-branched stent-graft technology. Implementation of inner branches in stent-grafts is gradually becoming more widespread for the treatment of aneurysms. This report supports the safe and high technical success rate of inner branched stent-grafts in treatment of pararenal abdominal aortic aneurysms.

单中心内分支内移植物治疗肾旁腹主动脉瘤的经验。
目的:报道肾旁动脉瘤患者应用内支内移植物治疗的单中心结果。材料和方法:这项回顾性研究分析了前瞻性收集的使用Artivion®E-xtra定制内移植物进行选择性内支血管内动脉瘤修复(iBEVAR)的患者数据。主要终点是iBEVAR后的临床和技术成功。次要终点是总生存率、随访期间靶血管通畅率、动脉瘤相关死亡率和无再干预。结果:在56个月的时间里,共有23名患者(19名男性;72.3±7.2岁)接受了iBEVAR治疗,平均随访15个月。96%的手术取得了技术上的成功,包括87个内部分支。报告了两例(8.3%)术中并发症(靶血管夹层),无需额外的再干预。两名(8.3%)患者在初次手术后30天内死亡。一个是由于呼吸衰竭,另一个是缺血性中风。在随访期间,3名患者(13%)需要再次干预,要么修复I型或III型内漏(n=2),要么放置髂骨分支装置,但在最初的iBEVAR手术中没有成功(n=1)。随访期间主要靶血管通畅率和无再干预率分别为98.9%和87%。我们没有发现与动脉瘤相关的死亡率。总生存率为78.3%。结论:本研究证实了先前的研究结果,即Artivion®E-xtra设计平台上的iBEVAR是一种有效、安全的手术,在治疗肾旁腹主动脉瘤方面取得了较高的技术成功率。临床影响:内支化支架移植物配置结合了FEVAR和外支化支架移植技术的优点。在动脉瘤的治疗中,内支在支架移植物中的应用越来越广泛。本报告支持内支化支架移植物治疗肾旁腹主动脉瘤的安全性和高技术成功率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.30
自引率
15.40%
发文量
203
审稿时长
6-12 weeks
期刊介绍: The Journal of Endovascular Therapy (formerly the Journal of Endovascular Surgery) was established in 1994 as a forum for all physicians, scientists, and allied healthcare professionals who are engaged or interested in peripheral endovascular techniques and technology. An official publication of the International Society of Endovascular Specialists (ISEVS), the Journal of Endovascular Therapy publishes peer-reviewed articles of interest to clinicians and researchers in the field of peripheral endovascular interventions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信